Steroidogenic factor 1 (SF1; Ad4BP/ NR5A1) plays key roles in gonadal development. Initially, the Sf1 gene is expressed in mouse fetal gonads of both sexes, but later is up-regulated in testes and down-regulated in ovaries. While Sf1 expression is activated and maintained by Wilms tumor 1 (WT1) and LIM homeobox 9 (LHX9), the mechanism of sexspecific regulation remains unclear. We hypothesized that Sf1 is repressed by the transcription factor Forkhead box L2 (FOXL2) during ovarian development. In an in vitro system (TM3 cells), up-regulation of Sf1 by the WT1 splice variant WT1-KTS was antagonized by FOXL2, as determined by quantitative RT-PCR. Using reporter assays, we localized the Sf1 proximal promoter region involved in this antagonism to a 674-bp interval. A conserved FOXL2 binding site was identified in this interval by in vitro chromatin immunoprecipitation. Introducing mutations into this site abolished negative regulation by FOXL2 in reporter assays. Finally, in Foxl2-null mice, Sf1 expression was increased 2-fold relative to wild-type XX fetal gonads. Our results support the hypothesis that FOXL2 negatively regulates Sf1 expression by antagonizing WT1-KTS during early ovarian development in mice.-Takasawa, K., Kashimada, K., Pelosi, E., Takagi, M., Morio, T., Asahara, H., Schlessinger, D., Mizutani, S., Koopman, P. FOXL2 transcriptionally represses Sf1 expression by antagonizing WT1 during ovarian development in mice. FASEB J. 28, 000 -000 (2014). www.fasebj.org
Steroidogenic factor 1 (SF1; Ad4BP/NR5A1) is a member of the nuclear receptor superfamily (1, 2) and plays a key role in the development of steroidogenic tissues, adrenal glands, and gonads (3, 4) . SF1 is essential for the initial step in the development of genital ridges in both sexes (5) and, consistently, gonad-specific Sf1-knockout models showed undescended, hypoplastic testes in XY mice and impaired follicle development with lack of corpora lutea in XX mice (6, 7) . During early gonadal development, Sf1 is expressed from at least 9.5 days post coitum (dpc) in the anlagen of gonads, the adrenogenital primordium, and its expression is initiated and/or maintained by a splice form of the Wilms tumor 1 (WT1) suppressor transcription factor, WT1-KTS, and by LIM homeobox 9 (LHX9) (8) .
In addition to initiating gonadal development, SF1 has an important role in testicular and ovarian development. After the expression of the male-determining gene sex-determining region Y (Sry), Sf1 expression is increased in developing testes, resulting in the sexually dimorphic expression pattern in gonads (3) . In developing testes, SF1 acts as a cofactor of SRY to up-regulate the Sertoli cell transcription factor gene SRY-box 9 (Sox9) via its testis-specific enhancer element (TES) (9) . Further, SF1 also cooperates with SOX9 to upregulate other Sertoli cell-specific genes, including Sox9 itself (9 -11) . In contrast to Sf1 expression in testes, expression in ovaries decreases after 12.5 dpc (3), but 1 Correspondence: Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Bunkyo, Tokyo 113-8510, Japan. E-mail: kkashimada.ped@tmd. ac.jp doi: 10.1096/fj.13-246108
Abbreviations: ChIP, chromatin immunoprecipitation; dpc, days post coitum; FOXL2, Forkhead box L2; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; LHX9, LIM homeobox 9; RPS29, ribosomal protein S29; SDHA, succinate dehydrogenase complex, subunit A; SF1, steroidogenic factor 1; SOX9, SRY-box 9; SRY, sex-determining region Y; WNT4, wingless-type MMTV integration site family, member 4; WT1, Wilms tumor 1 how Sf1 expression is down-regulated during early ovarian development remains unclear.
Forkhead box L2 (FOXL2) is a member of the Forkhead transcription factor family and is expressed mainly in somatic cells of XX gonads and in developing eyelids (12) . The phenotypes of mammalian models of Foxl2 deficiency vary from XX sex reversal in goats (13) to ovarian failure in mice and humans (12, 14, 15) . FOXL2 has been reported to up-regulate ovary-specific genes such as aromatase, follistatin, and BMP2 (16 -18) , and XX Foxl2 Ϫ/Ϫ mice are sterile, with small and disorganized ovaries in which primary ovarian follicles are not formed (14) . FOXL2 is considered essential for ovarian folliculogenesis and granulosa cell development and acts independently of another ovary-determining gene, wingless-type MMTV integration site family, member 4 (Wnt4; ref. 18) .
In addition to directly activating the female pathway, FOXL2 has been suggested to suppress the opposing male pathway. FOXL2 represses SF1-induced Cyp17 and Cyp26b1 transcription during gonadal development (19, 20) , and ablation of Foxl2 in adult mouse ovaries results in an up-regulation of Sox9 expression, leading to ovary-to-testis transdifferentiation (21) . Further, immunohistochemical analyses of XY pos ovotestes have revealed that SF1 expression is decreased in FOXL2-positive regions from 13.5 dpc onward (22) . On the basis of these findings, we speculated that FOXL2 is a good candidate to suppress Sf1 transcription during ovarian development.
Here, we report a suite of in silico, in vitro, and in vivo analyses and experiments that together indicate that FOXL2 directly antagonizes the positive regulation of Sf1 by WT1-KTS during early ovarian development in mice by binding to critical sequences in the Sf1 proximal promoter. Our findings provide new mechanistic insight into the sex-specific regulation of gonadal development, and support the emerging view that correct testicular or ovarian development depends on a balance of molecular signals.
MATERIALS AND METHODS

Mouse strains
Protocol and use of animals were approved by the Center for Experimental Animals of Tokyo Medical and Dental University. Mouse embryos were collected from timed mating of the ICR outbred strain, with noon of the day on which the mating plug was observed designated as 0.5 dpc. The sex of the embryos was determined at 11.5 dpc using genotyping PCR assay on tissue lysate, as described previously (23) and at 12.5-14.5 dpc by gonadal morphology. The generation of Foxl2-null mice was reported previously (14) , and the mice were maintained on a mixed C57B6/J/129/SVJ genetic background.
Plasmid construction
An Sf1 promoter fragment encompassing nt Ϫ589 to ϩ85 (24) was generated by PCR using genomic C57BL/6J DNA as a template and cloned into the SacI and KpnI sites of the pGL4.10 luciferase reporter vector (Promega, Madison, WI, USA) and named PGL4-Sf1p. The PGL4-Sf1p with mutation in the putative FOXL2 response element (GCCAAGGT to GCTGCATT) was generated using the QuikChange sitedirected mutagenesis kit (no. 200518; Stratagene, La Jolla, CA, USA), according to the manufacturer's instructions. Primers used for generating the Sf1p-MG are shown in Table 1 . HA-Wt1-KTS (ϩexon5, ϪKTS), HA-Wt1ϩKTS (ϩexon5, ϩKTS), Lhx9, and Foxl2 expression construct was prepared as previously reported (8, 14, 16) . The Myc-tagged Foxl2 expression plasmid was generated by inserting an MYC tag to the above-mentioned Foxl2 expression constructs (5= side) in frame. All plasmids were sequence verified before use.
Transfection into TM3 cells
The murine testicular somatic cell line TM3 was obtained from American Type Culture Collection (Manassas, VA, USA; ref. 25) and cultured in DMEM (Life Technologies, Carlsbad, CA, USA) supplemented with 10% FBS (Invitrogen, Carlsbad, CA, USA) at 37°C in 5% CO 2 . Cells were transfected with expression vectors using Lipofectamine 2000 (Invitrogen), according to the manufacturer's instructions. The total amount of transfected plasmids was standardized using the empty expression plasmid.
Quantitative RT-PCR (qRT-PCR)
qRT-PCR analyses of TM3 cells and mouse gonads were conducted as follows. Cells were incubated in 6-well plates and collected at 48 h post-transfection. Embryonic gonads without mesonephros were dissected in ice-cold PBS at the appropriate stages. Total RNA from cells and embryonic gonads was isolated using the RNeasy Mini Kit (Qiagen, Valencia, CA, USA), including DNase treatment. Total RNA (500 ng for TM3 cells or 200 ng for gonads) was used as a template for synthesis of cDNA using SuperScript III (Invitrogen) and random primers (Invitrogen), according to the manufacturer's instructions. cDNA samples were diluted 1:4, and 1 l was used in each 20 l of qRT-PCR reaction, containing SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA, USA). Transcript levels were analyzed on a Light Cycler 480 System II (Applied Roche, Basel, Switzerland) over 40 cycles of 95°C for 10 s, 60°C for 10 s, and 72°C for 15 s, preceded by an initial 5-min step at 95°C. Glyceraldehyde-3-phosphate dehydrogenase (Gapdh) for TM3 cells and ribosomal protein S29 (Rps29) for embryonic gonads (26) were used as the normalizing gene to standardize qRT-PCR data.
For Foxl2-null mice, we collected gonadal samples at 13.5 dpc, 16.5 dpc, and P0, and total RNA was obtained from dissected gonads by column extraction (RNeasy Mini Kit; Qiagen) followed by linear RNA amplification using WTOvation Pico (Nu-GEN, San Carlos, CA, USA). qRT-PCR was performed as reported previously (27) and succinate dehydrogenase complex, subunit A (Sdha) was used as the housekeeping gene to standardize the data (26) . The relative expression levels to XX wild-type mice were calculated.
All qRT-PCR primers are listed in Table 1 . It has been reported that the ratio between Wt1ϩKTS and Wt1-KTS is nearly constant in all cell types (28 -30), so we considered the total level of the Wt1 expression represents the Wt1-KTS expression in vivo. The means Ϯ sd of 3 biological replicates measured in triplicate were calculated. Statistical significance of qRT-PCR analysis of TM3 cells was assessed using 1-way ANOVA followed by a Tukey-Kramer post hoc test. Unpaired Student's t test was used for qRT-PCR analysis of Foxl2-null mice to demonstrate statistical significance of differences between the control and experimental sample.
Luciferase assay
TM3 cells were transiently cotransfected with a constant amount of Sf1p-LUC or Sf1p-MG (200 ng), and pRL-SV40 luciferase reporter plasmid (10 ng; Promega) with expression plasmids that are 200 ng of HA-Wt1-KTS and 0, 200, or 400 ng of Foxl2, respectively. The total amount of plasmid DNA for each transfection was kept constant. Cells were harvested and lysed 48 h after transfection, and both firefly and Renilla luciferase activity was measured using a dual luciferase reporter assay system (Promega). The firefly luminescence signal was normalized on the basis of the Renilla luminescence signal, and the means Ϯ sd of the relative signal levels to negative control in triplicate were calculated. Statistical significance of luciferase assay was assessed using 1-way ANOVA followed by a Tukey-Kramer post hoc test.
Chromatin immunoprecipitation (ChIP) assay
ChIP assays were performed with ChIP-IT express enzymatic kit (Active Motif, Carlsbad, CA, USA), according to the manufacturer's instructions. In brief, TM3 cells were transiently transfected with the Myc-Foxl2 and/or HA-Wt1-KTS expression plasmid. Cells were cross-linked 48 h after transfection with 1% formaldehyde. Cells were then washed in ice-cold PBS and resuspended in lysis buffer containing protease inhibitor mixture. We fragmented the chromatin in the suspension by using the enzyme (Active Motif) and homogenized the sample. Then, the chromatin solution was immunoprecipitated with polyclonal antibody: anti-MYC antibody ChIP grade (ab9132; Abcam, Cambridge, UK) or anti-HA tag antibody ChIP grade (ab9110; Abcam), or negative control IgG (ChIP-IT control kit; Active Motif), incubating with protein G magnetic beads at 4°C. Immune complexes were washed, and formaldehyde cross-links were reversed by heating. Proteinase K was added to the reaction mixtures and incubated at 37°C for 1 h. DNA from the immunoprecipitates and control input DNA were purified and then analyzed by qRT-PCR. The primers for PCR amplification of the proximal Sf1 promoter region spanning the putative FOXL2 response element, the WT1 binding element (8) , and negative control are shown in Table 1 and Fig. 3B , F. The volume of 1 l DNA samples was used in each 20 l of PCR reaction, containing SYBR Green PCR Master Mix. DNA levels were analyzed on a Light Cycler 480 System II over 40 cycles of 95°C for 10 s, 58°C for 20 s, and 72°C for 20 s in a 2-step thermal cycle, preceded by an initial 5-min step at 95°C.
The means Ϯ sd of 3 biological replicates measured in triplicate were calculated. We used an unpaired Student's t test for real-time PCR analysis of ChIP assays to demonstrate statistical significance of differences between the control input and the given sample.
Homology analysis
Phylogenetic analysis was performed on the Sf1 proximal promoter sequence of rats, humans, cows, dogs, and mice. Each sequence was obtained from the Ensembl database (http://www.ensembl.org) and aligned using the Basic Local Alignment Search Tool (BLAST; U.S. National Center for Biotechnology Information, Bethesda, MD, USA; http:// blast.ncbi.nlm.nih.gov/blast.cgi). 
RESULTS
Decrease in Sf1 expression coincides with up-regulation of Foxl2 in mouse fetal ovaries
To study in detail the relationship between the temporal expression patterns of Sf1, Foxl2, and other candidate regulatory genes in the ovary after sex determination, we first performed qRT-PCR analysis of 11.5-to 14.5-dpc mouse gonads of both sexes. As previously reported (3, 31), a sexually dimorphic expression pattern of Sf1 was observed by 12.5 dpc (Fig. 1A) , and Foxl2 expression was sexually dimorphic, with higher expression in XX gonads at all stages investigated (Fig. 1A) .
On the other hand, expression of Wt1 and Lhx9, genes that have been reported to drive Sf1 expression during early gonadal development (8), did not show any difference between XY and XX gonads (Fig. 1A) , suggesting that Wt1 and Lhx9 do not contribute to the sexually dimorphic expression pattern of Sf1. The reciprocal relationship between the dynamics of Sf1 and Foxl2 expression in vivo (Fig. 1B) supports the hypothesis that FOXL2 suppresses the expression of Sf1 during early ovarian development.
FOXL2 negatively regulates Sf1 expression induced by WT1-KTS in vitro
To determine whether FOXL2 has a role in regulating Sf1, we performed in vitro experiments using the mouse gonadal cell line TM3 (25, 32 Fig. 2A) . Next, we investigated the potential involvement of FOXL2 in Sf1 regulation by introducing a Foxl2 expression plasmid into TM3 cells together with a Wt1-KTS expression plasmid or an Lhx9 expression plasmid. In agreement with our hypothesis, FOXL2 strongly suppressed WT1-KTS-induced Sf1 expression (Fig. 2B) . LHX9 increased Sf1 expression ϳ1.2-fold, and this effect was not significantly suppressed by FOXL2 in TM3 cells (Fig. 2B, C) . On the basis of those findings, we concluded that FOXL2 negatively regulates Sf1 expression by suppressing the action of WT1-KTS, and, Figure 1 . Sf1 expression decreased from 11.5 dpc and coincided with a dramatic up-regulation of Foxl2 expression. A) Time course of Sf1, Foxl2, Wt1, and Lhx9 expression during mouse gonadal development. Data sets represent mRNA expression relative to Rps29, means Ϯ sd of 3 biologically independent experiments performed in triplicate. Bold and dotted traces indicate ovary and testis, respectively. Statistically significant differences between 11.5 dpc and other time points of Sf1 expression levels in 46,XX gonads were analyzed by using Student's t test. ***P Ͻ 0.001. B) Time course of Sf1 and Foxl2 expression during mouse ovarian development, with maximum expression levels adjusted to 100%. consequently, focused on the mechanism of the antagonism between WT1-KTS and FOXL2.
FOXL2 directly binds to the proximal Sf1 674-bp promoter and represses Sf1 expression in vitro
A 674-bp Sf1 promoter fragment was previously reported to activate LacZ expression in the indifferent gonad in transgenic mouse embryos at 11.5 dpc (8), suggesting that the promoter fragment harbors elements that are sufficient to direct Sf1 expression in that tissue in vivo. To elucidate how FOXL2 suppresses the Sf1 expression driven by WT1-KTS, we used this promoter linked with the luciferase reporter gene to conduct a series of in vitro cotransfection reporter assays in TM3 cells.
In agreement with our analysis of endogenous Sf1 levels ( Fig. 2A) , cointroduction of Wt1-KTS expression constructs with the Sf1-luciferase reporter construct PGL4-Sf1p resulted in a Ͼ5-fold induction of reporter activity (Fig. 3A) . Further, cointroduction of the Foxl2 expression plasmid with Wt1-KTS expression plasmid suppressed reporter activity in a dose-dependent manner (Fig. 3A) .
The binding site for FOXL2, or FOXL2 response element (FLRE), was defined in previous studies as 5=-GTCAAGG(T/C)-3= (33). We identified a similar motif, GCCAAGGT, in the 674-bp Sf1 promoter, between positions Ϫ229 and Ϫ222 bp relative to the transcription start site (Fig. 4) . This site, designated as FLB1, was located between the WT1 binding site (Ϫ318 to Ϫ309 bp) and the transcription start site of the Sf1 gene (Fig. 3B) , raising the possibility that, by binding to FLB1, FOXL2 may directly interact with, or sterically hinder, WT1-KTS in a transcriptional complex. We performed in vitro ChIP experiments to evaluate the FOXL2 binding to FLB1 by introducing MYC-tagged FOXL2 into TM3 cells. A ChIP assay using a FOXL2-specific antibody revealed that FOXL2 specifically binds to FLB1 within the Sf1 proximal promoter (Fig. 3C) .
Next, to confirm that the mechanism by which FOXL2 suppresses Sf1 activation involves binding to FLB1, we introduced mutations in FLB1 within the Sf1 promoter-luciferase construct that would be predicted to abolish its ability to bind FOXL2 (Fig. 3D) . Luciferase assays in TM3 cells showed that the suppressive action of FOXL2 on WT1-KTS was completely abolished by the mutations (Fig. 3E) . We also asked whether FOXL2 interferes with the ability of WT1-KTS to bind to the Sf1 proximal promoter by conducting in vitro ChIP analysis of WT1-KTS in the presence or absence of FOXL2 (Fig. 3F) . We found that WT1-KTS interaction with the Sf1 proximal promoter was not compromised by FOXL2 (Fig. 3G) . Taken together, these results indicate that the suppressive effect of FOXL2 depends on direct binding to the Sf1 proximal promoter and that this binding does not block access of WT1-KTS to the promoter.
Homology analysis revealed that the sequence of the ChIP analysis using anti-HA or control IgG antibodies. Samples were analyzed by qPCR using a primer set encompassing the WT1-KTS biding site or a primer set for negative control (NC2). Shaded bars and open bars indicate samples treated with anti-HA or anti-IgG antibodies, respectively. Statistical significance was determined using 1-way ANOVA followed by a Tukey-Kramer post hoc test. NS, not significant. *P Ͻ 0.05, **P Ͻ 0.01, ***P Ͻ 0.001.
proximal Sf1 promoter was conserved among eutherians, but not marsupials and monotremes. Further, every conserved Sf1 promoter had the FOXL2 binding site FLB1, suggesting that FOXL2 binding to FLB1 has an essential role in regulating Sf1 promoter function (Fig. 4) .
Sf1 expression during early ovarian development is suppressed by FOXL2 in vivo
Finally, to determine whether Sf1 expression is suppressed by FOXL2 in vivo, we analyzed ovarian Sf1 expression in Foxl2-null mice. Sf1 expression in ovaries of Foxl2-null mice was significantly higher than that in wild-type mice at 13.5 dpc and 16.5 dpc (Fig. 5A) . However, at P0, there was no significant difference between Foxl2-null and wild-type mice. Furthermore, expression of Wt1 and Lhx9 was not affected in Foxl2-null mice at any stage examined (Fig. 5B, C) , suggesting that Sf1 expression in Foxl2-null mice was not affected by altered expression levels of the upstream molecules, WT1 or LHX9. Together, these findings suggest that FOXL2 suppresses Sf1 expression during fetal ovarian development in a stage-dependent manner in vivo and that the involvement of FOXL2 is limited to the earlier stages, i.e., up to 16.5 dpc, of ovarian development.
DISCUSSION
The temporal expression pattern of Sf1 during gonadal development is tightly regulated. In the first step, Sf1 is up-regulated by WT1-KTS and LHX9, initiating gonadal development (8) . Subsequently, after sex determination, Sf1 expression is increased in testes and suppressed rapidly in ovaries (3). It is unlikely that WT1 or LHX9 play a major role in the sexually dimorphic Sf1 expression in gonads, based on our qRT-PCR analysis showing that the expression levels of Wt1 and Lhx9 did not change dramatically from 11.5 to 14.5 dpc and were not sexually dimorphic. Those findings suggest that other testis-or ovary-specific factors are involved in Sf1 gene regulation after sex determination. In testes, SOX9 is the most likely candidate for the testis-specific up-regulation of Sf1 expression, given that in AMH-Cre: Sox9 flox/flox mice, in which Sox9 activity is ablated after sex determination, leading to a testicular phenotype in XX mice, Sf1 expression in fetal testes was remarkably decreased (34) . Furthermore, SOX9 binds to the proximal promoter of Sf1 and positively regulates the promoter in a reporter assay (35) . Thus, it appears that WT1 and LHX9 act to initiate and/or maintain expression of Sf1 in fetal genital ridges of both sexes, after which SOX9 acts to increase the expression level of Sf1 as the testes develop further.
On the other hand, the mechanism by which Sf1 is suppressed in the developing ovary has not been elucidated. We show that the temporal expression levels of Wt1 and Lhx9 in the developing ovary were not changed, and we reasoned that an ovarian transcription factor might play a role in a suppressing Sf1 expression. In agreement with our hypothesis, we show here that FOXL2 represses Sf1 expression during ovarian development, that this effect is direct and specifically mediated by binding to a promoter motif to antagonize WT1-KTS, and that this mechanism is likely to be part of a conserved pathway of sex-specific gene regulation in gonadogenesis in eutherian mammals. This is the first study to reveal the regulation of the sexual dimorphic expression pattern of Sf1, and on the basis of our findings, we present a model of Sf1 regulation before and after sex determination in Fig. 6 .
FOXL2 has an important role in ovarian development (36) and is involved in the regulation of other ovarian genes, such as aromatase, follistatin, and Bmp2 (16 -18) . In addition, FOXL2 has been reported to antagonize components of the testicular pathway. For example, FOXL2 synergistically interacts with estrogen receptors ␣ and ␤ to directly repress Sox9 up-regulation via TESCO (21) . FOXL2 also interacts directly with SF1, resulting in repression of testis-expressed SF1 target genes, such as Cyp17 (19) . A novel mechanism by which FOXL2 suppresses Sf1, revealed in the present study, is to antagonize WT1-KTS action by directly binding to the Sf1 promoter. This antagonism by FOXL2 prevents WT1-KTS from maintaining Sf1 transcription, resulting in down-regulation of Sf1 expression in the developing ovary. Our in vitro ChIP and luciferase assays suggest that FOXL2 directly interferes with the action of WT1-KTS or its coactivators rather than inhibiting access of WT1-KTS to the proximal promoter. This interference may involve changes to chromatin architecture that influence the accessibility of other regulatory factors; this possibility remains to be investigated in future studies. Similarly, it remains to be determined whether post-translational modifications such as SUMOylation and phosphorylation (37) , which are known to modulate FOXL2 activity, play a role in this response.
Our mechanistic studies focused on a 674-bp Sf1 promoter fragment encompassing nt Ϫ589 to ϩ 85. We reasoned that because this fragment had been previously reported to activate LacZ expression in the indifferent gonad in transgenic mouse embryos at 11.5 dpc by binding both LHX9 and WT1-KTS (8) , it would also likely be the target of any mechanism interfering with the action of LHX9 and/or WT1-KTS, such as the observed suppression by FOXL2. Our identification of a FOXL2 binding site in this region that, when mutated, no longer mediates down-regulation of Sf1 reporter constructs validates this approach. Beverdam et al. (38) showed that GFP reporter constructs driven by the same promoter fragment are expressed in both the testis and the ovary at 13.5 dpc, but expression levels were not quantified, and it is possible that some suppression occurred in the ovary. More recently, a study using the overlapping Sf1 promoter fragment Ϫ734 to ϩ60 bp driving reporter constructs introduced into cultured gonad explants found that substantial reporter activity 24 h after the introduction of the reporters in 13.5-and 15.5-dpc ovaries (39) . Whether the apparent discrepancy between the findings of that study and our present data results from differences in experimental system, time points analyzed, or extent of the promoter fragments used is not clear, and further studies will be required to resolve this issue.
Our analysis of Foxl2-null mice revealed suppression of Sf1 expression by FOXL2 at earlier stages of ovarian development, i.e., up to 16.5 dpc, but not beyond. We presume that FOXL2 might not be the only factor to suppress Sf1 expression during ovarian development, and that, at later fetal stages, Sf1 expression in ovaries is actively suppressed by other molecules or passively down-regulated by escaping from WT1 and LHX9 transactivation. Further study is necessary to test these possibilities.
To date, few molecules have been reported to antagonize transactivation by WT1. Considering the essential role of WT1 in development of many organs other than the gonads, including the kidney and heart (40), any mechanism that antagonizes WT1 could also have a broader role in the development of the fetus. Therefore, any antagonistic mechanism would need to be contained in a highly temporally and spatially specific manner. The antagonistic mechanism of FOXL2 revealed in the present study has two features that are consistent with our hypothesis. First, FOXL2 is expressed in limited organs, such as pituitary glands, eyelids, and ovaries (14, 15) , and second, FOXL2 antagonizes WT1 specifically via the transient specific promoter that drives Sf1 expression during earlier stages of gonadal development. The mechanism of Sf1 regulation revealed in this study provides a framework for further studies of the antagonistic regulatory relationship between WT1 and other transcription factors in the development of other organ systems such as kidneys and hearts.
In summary, our study provides new mechanistic insight into the differentiation of ovaries, about which relatively little is currently known compared to testis differentiation pathways. Further studies will be required to illuminate the relationship between the FOXL2-SF1-aromatase-follistatin-BMP2 axis of ovarian determination and differentiation and the WNT4/ RSPO1/␤-catenin axis, which remains poorly understood. Greater appreciation of these issues will lead to improved understanding of the molecular causes of 46,XX sex reversal and/or ovarian dysgenesis syndromes in humans.
